Y-mAbs Therapeutics, Inc.: restructuring charge — Y-mAbs realigns into two units, cuts ~13% staff; FY24 rev ~$88M; GD2-SADA data Q2 2025

Y-mAbs Therapeutics, Inc.

Preliminary FY2024 total net revenue ~$88M (guidance $87-95M); cash ~$67M; cash investment ~$11M (below $15-20M guidance).
Workforce reduction of up to ~13% as part of realignment into DANYELZA and Radiopharmaceutical business units.
SVP/Chief Commercial Officer Susan Smith departs April 9, 2025; Doug Gentilcore named SVP Danyelza Unit Head, Natalie Tucker promoted to SVP Radiopharma Head.
GD2-SADA Phase 1 Part A (21 patients) well-tolerated, no DLTs; Part A data expected in Q2 2025.
CD38-SADA first patient dosing expected Q1 2025; potential DANYELZA ex-US approval in 2025.

item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Susan Smith

Senior Vice President and Chief Commercial Officer

Y-mAbs Therapeutics, Inc.

Effective: 2025-04-09
Filed: January 10, 2025, 6:59 PM ET

Susan Smith, the Company’s Senior Vice President and Chief Commercial Officer, will be departing from the Company on April 9, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Smith departed as Senior Vice President and Chief Commercial Officer at Y-mAbs Therapeutics, Inc..

Action: will be departing
Role: Senior Vice President and Chief Commercial Officer

Exact text from the filing

Susan Smith, the Company’s Senior Vice President and Chief Commercial Officer, will be departing from the Company on April 9, 2025.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Y-mAbs Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.6 million affecting not explicitly segmented but refers to two business units: DANYELZA and Radiopharmaceuticals (up to approximately 13%).

Type: restructuring
Charge: up to approximately $2.6 million
Affected area: not explicitly segmented but refers to two business units: DANYELZA and Radiopharmaceuticals
Headcount: up to approximately 13%

Exact text from the filing

healthcare coverage assistance. As a result of the reduction in workforce and realignment plan, the Company expects to incur restructuring expenses of up to approximately $2.6 million, consisting predominantly of cash-related notice and severance payments of up to approximately $2.1 million and acceleration of stock-based compensation of up to approximately

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001558370-25-000105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.